Additionally developed models are based on TDP-43 (Wegorzewska et al., 2009; Liu et al., 2013; Yang et al., 2014) and FUS mutations (Verbeeck et al., 2012), but none of these models is currently used to study the pathogenesis of ALS and to test new drugs. This evidence concerns the gene FUS and amyotrophic lateral sclerosis.